Medicinal Cannabis

The importance of healthy scepticism
A potted history...

• 3000BCE- Indica in India
• 1500BCE- in Ancient Western writing
• 1800 CE- introduced into the West
• 1850 CE- US Pharmacopoeia (til 1937)
• Mid twentieth century- criminalised

• Early twenty first century- movement for social acceptance via medicalisation
What we take for granted when we prescribe....

1. We know what we are prescribing
   – Same every time
   – The dose is reliable
   – The kinetic and dynamics are examined

2. Its one thing that works
   – (expect for special foods)

3. The risks and benefits are spelled out

4. There is evidence of effectiveness
New Zealand Health Survey 2012/13: characteristics of medicinal cannabis users

Morgan J Pledger, Greg Martin, Jacqueline Cumming

ABSTRACT

AIM: To explore the characteristics of medicinal and non-medicinal cannabis users, and the conditions that were treated with cannabis.

METHODS: The data come from the New Zealand Health Survey 2012/2013, which sampled 13,099 people, aged 15+ years, living in private or non-private dwellings in New Zealand. Participants self-reported cannabis use and were put into groups: 1) non-users; 2) ex-users; 3) last year users—non-medicinal; 4) last-year users—medicinal. Prevalence was reported for the major demographic subgroups: sex, age and ethnicity. Repression models were then utilized to find associations between demographic characteristics and cannabis use for groups 3 and 4.

RESULTS/CONCLUSIONS: About five percent (4.6%, 95% CI 4.1–5.1) of those aged 15+ report using cannabis medicinally. This use was associated with being male, younger, less well-educated and relatively poor. While Maori have the highest prevalence of medicinal use, European NZ/Others make up 67.9% (95% CI 62.7–72.6) of medicinal users. Reported medicinal use was associated with reported conditions that were typically hard to manage: pain, anxiety/nerves and depression. Medicinal users were more likely to report chronic pain and pain interfering, moderately or more, with housework and other work.

In current illegal to cultivate, possess, supply and use cannabis through the Misuse of Drugs Act 1975. However, the Minister of Health is able to approve the medicinal use of the cannabis plant, although in practice, the decision has been delegated to the Associate Health Minister: Hon Peter Dunne. In 2013, the first application was approved for the use of cannabis oil for a case of “status epilepticus.” In the context of this application, Hon Peter Dunne said that this should not be seen as a “significant change in policy.”

In 2014, consent was given for use of the cannabis medicine, Sativex, in New Zealand. This medicine in an extract of the cannabis plant and is a standardised product with known levels of psychoactive content—unlike illicit cannabis, which can vary greatly in potency. Sativex is available on prescription to the Ministry of Health by the patient, the patient’s GP and specialist. Sativex is not fully funded by PHARMAC.

apparitions to prescribe Sativex had been approved in New Zealand. In the same month, a patient who had recurring seizures that her specialist said could lead to coma and death had the medicine fully funded.

As cannabis use is illegal, it is difficult to get information about who is using cannabis medicinally and for what reasons. In 2009, the Green Party of New Zealand randomly surveyed general practitioners and selected hospital specialists about their views on medicinal cannabis. The results showed that 80% of these doctors knew they had patients who were using cannabis medicinally. They also showed that 80% of doctors would consider prescribing medicinal cannabis products if they were legally allowed and 10% of doctors had patients they felt could benefit from cannabis.

In 2006, the Green Party of New Zealand introduced the Misuse of Drugs (Medicinal Cannabis) Amendment Bill, but it was
New Zealand Health Survey 2012/13: characteristics of medicinal cannabis users

Morgan J Pledger, Greg Martin, Jacqueline Cumming

ABSTRACT

AIM: To explore the characteristics of medicinal and non-medicinal cannabis users, and the conditions that were treated with cannabis.

METHODS: The data comes from the New Zealand Health Survey 2012/2013, which sampled 13,089 people, aged 15+ years, living in private or non-private dwellings in New Zealand. Participants self-reported cannabis use and were put into groups: 1) non-users, 2) ex-users, 3) last year users—non-medicinal, 4) last year users—medicinal. Prevalence was reported for the major demographic subgroups; sex, age and ethnicity. Repression models were then used to find associations between demographics characteristics and cannabis use for groups 3 and 4.

RESULTS/CONCLUSIONS: About five percent (4.6%, 95% CI 4.1–5.1) of those aged 15+ report using cannabis medicinally. This use was associated with being male, younger, less well-educated and relatively poor. While Māori have the highest prevalence of medicinal use, European NZ/Others make up 67.9% (95% CI 62.7–72.6) of medicinal users. Reported medicinal use was associated with reported conditions that were typically hard to manage: pain, anxiety/nerves and depression. Medicinal users were more likely to report chronic pain and pain interfering, moderately or more, with housework and other work.

In 2010, consent was given for use of the cannabis medicine, Sativex, in New Zealand. This medicine is an extract of the cannabis plant and is a standardised product with known levels of psychoactive content—unlike illicit cannabis, which can vary greatly in potency. Sativex is available on prescription to the Ministry of Health by the patient, the patient's GP and specialist. 

Sativex is not fully funded by PHARMAC; applications to prescribe Sativex had been approved in New Zealand. In the same month, a patient who had been given Sativex to treat his seizures said that it had lead to coma and death had the medicine fully funded. As cannabis use is illegal, it is difficult to get informed about who is using cannabis medicinally and for what reasons. In 2005, the Green Party of New Zealand randomly surveyed general practitioners and selected hospital specialists about their views on medicinal cannabis. The results showed that 30% of these doctors knew that they had patients who were using cannabis medicinally. They also showed that 32% of doctors would consider prescribing medicinal cannabis products if they were legally allowed and 16% of doctors had patients they felt could benefit from cannabis.

In 2006, the Green Party of New Zealand introduced the Māui of Drugs (Medical Cannabis) Amendment Bill, but it was...
Potential Harms

Conclusive evidence
- Chronic bronchitis, respiratory sx
- Motor vehicle crash
- Low birth weight
- Assoc. w/schizophrenia, other psychosis

Moderate evidence
- "Problem cannabis use" if depressed
- No inc risk lung, or head & neck cancer

Limited evidence
- Inc. ischemic CVA
- Inc. MI
- COPD risk

Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study

Gabrielle Campbell, Wayne D Hall, Amy Peacock, Nicholas Lintzeris, Raimondo Bruno, Bronwyn Lawrance, Suzanne Nielsen, Milton Cohen, Gary Chan, Richard P Mattick, Fiona Blyth, Marian Shanahan, Timothy Dobbin, Michael Farrell, Louisa Degenhardt

Summary
Background Interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain is increasing, because of their potential to reduce opioid dose requirements. We aimed to investigate cannabis use in people living with chronic non-cancer pain who had been prescribed opioids, including their reasons for use and perceived effectiveness of cannabis; associations between amount of cannabis use and pain, mental health, and opioid use; the effect of cannabis use on pain severity and interference over time; and potential opioid-sparing effects of cannabis.

Interpretation Cannabis use was common in people with chronic non-cancer pain who had been prescribed opioids, but we found no evidence that cannabis use improved patient outcomes. People who used cannabis had greater pain and lower self-efficacy in managing pain, and there was no evidence that cannabis use reduced pain severity or interference or exerted an opioid-sparing effect. As cannabis use for medicinal purposes increases globally, it is important that large well designed clinical trials, which include people with complex comorbidities, are conducted to determine the efficacy of cannabis for chronic non-cancer pain.
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study

Gabrielle Campbell, Wayne D Hall, Amy Peacock, Nicholas Lintzeris, Raimonda Bruno, Bronya Larance, Suzanne Nielsen, Milton Cohen, Gary Chan, Richard P Mattick, Fiona Blyth, Marian Shanahan, Timothy Dobbin, Michael Farrell, Louisa Degenhardt

Summary

Background Interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain is increasing, because of their potential to reduce opioid dose requirements. We aimed to investigate cannabis use in people living with chronic non-cancer pain who had been prescribed opioids, including their reasons for use and perceived effectiveness of cannabis; associations between amount of cannabis use and pain, mental health, and opioid use; the effect of cannabis use on pain severity and interference over time; and potential opioid-sparing effects of cannabis.

Interpretation Cannabis use was common in people with chronic non-cancer pain who had been prescribed opioids, but we found no evidence that cannabis use improved patient outcomes. People who used cannabis had greater pain and lower self-efficacy in managing pain, and there was no evidence that cannabis use reduced pain severity or interference or exerted an opioid-sparing effect. As cannabis use for medicinal purposes increases globally, it is important that large well designed clinical trials, which include people with complex comorbidities, are conducted to determine the efficacy of cannabis for chronic non-cancer pain.
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study

Gabrielle Campbell, Wayne D Hall, Amy Peacock, Nicholas Lintzeris, Raimondo Bruno, Briony Larance, Suzanne Nielsen, Milton Cohen, Gary Chan, Richard P Mattick, Fiona Blyth, Marian Sharahan, Timothy Dobbs, Michael Farrell, Louisa Degenhardt

Summary

Background Interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain is increasing, because of their potential to reduce opioid dose requirements. We aimed to investigate cannabis use in people living with chronic non-cancer pain who had been prescribed opioids, including their reasons for use and perceived effectiveness of cannabis associations between amount of cannabis use and pain, mental health, and opioid use; the effect of cannabis use on pain severity and interference over time; and potential opioid-sparing effects of cannabis.

Interpretation

Cannabis use was common in people with chronic non-cancer pain who had been prescribed opioids, but we found no evidence that cannabis use improved patient outcomes. People who used cannabis had greater pain and lower self-efficacy in managing pain, and there was no evidence that cannabis use reduced pain severity or interference or exerted an opioid-sparing effect. As cannabis use for medicinal purposes increases globally, it is important that large well-designed clinical trials, which include people with complex comorbidities, are conducted to determine the efficacy of cannabis for chronic non-cancer pain.
Fee for service doctors dispense more antibiotics in Canada

Greg Basky, Saskatoon, Canada

Doctors paid on a fee for service basis write more prescriptions for antibiotics than their salaried counterparts, according to recently published Canadian research.

Researchers found New-
So what to tell your patients.....

"It's just a simple Rorschach ink-blot test, Mr. Bromwell, so just calm down and tell me what each one suggests to you."
Evidence based use of a cannabinoid does not equal socially condoning the cannabis recreationally.
Cannabis has some evidence in very few conditions, benefits and harms need to be balanced.
Not prescribing is not the same as doing nothing
Smoking cannabis is not cool
Taking cannabis when your young is not cool
• So get engaged

D-day 4\textsuperscript{th} December 2019